Myriad Genetics, Inc. (MYGN) - New FusionIQ Short Squeeze
Myriad Genetics, Inc. (MYGN) which develops and commercializes genes involved in major common diseases including cancer, cardiovascular disease, and central nervous system disorders scored a new FusionIQ short squeeze yesterday as shares which have 25 percent of their float short shot up aggressively on close to 2 times its normal 21-day average volume. 
 
Additionally, MYGN shares also scored a new FusionIQ timing BUY signal yesterday. 

Comments
Leave a comment
Name
Email Address
URL
Remember personal info?
Comments
Blog Home
RSS Feed
Categories
Barron's
Breakouts/Breakdowns
ChartWatch
Company in the News
Equity Timing Signals (Buy/Sell)
Market Data
Media
New Highs
Sector Group Rankings
Short Squeeze Screen
Stock Analysis
Total Stocks Rankings
Archives
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007